【作者】 邹颖； 冯琳； 戴惠珍；

【Author】 ZOU Ying FENG Lin (The First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,China) DAI Huizhen (Research Institute for Medicine Information of Jiangsu Province,Nanjing 210004,China)

【机构】 南京医科大学第一附属医院药剂科； 江苏省医药情报研究所；

【摘要】 目的:探讨长江流域六城市157家入网医院2007年调脂药物利用情况与发展趋势。方法:对长江流域157家入网医院2007年应用调脂药物的种类、销售金额及用药频度等进行分析排序。结果:2007年长江流域157家医院调脂药的销售金额同比增长32.76%。2007年入网医院调脂药销售总金额为16676.60万元,其中他汀类占总销售金额的72.73%。六市用药金额及用药频度排序中主要包括阿托伐他汀、辛伐他汀、血脂康、非诺贝特。结论:他汀类药物占有调脂治疗的主导地位,辛伐他汀、阿托伐他汀为六市最常使用的品种。以血脂康为代表的中成药销售前景看好。更多还原

【Abstract】 OBJECTIVE:To evaluate the utilization and tendency of fat-modulating drugs in 157 hospitals of 6 cities in the Yangtze River Valle. METHORD:The use of fat-modulating drugs agents in 157 hospitals of 6 cities in 2007 were analyzed statistically in terms of drug varieties,consumption and DDDs. RESULTS:The total annual cost of the fat-modulating drugs used in 6cities was 1.67 billion yuan in 2007,increasing by 32.76%,as compared with that in 2006.The average consumption of the statins accounted for 72.73% of the total cost in2007.The atorvastatin,simvastatin,xuezhikang,and fenofibrate dominated in the ranking of sum and DDDs.CONCLUSION:The statins was the major choice in treatment for hyperlipoidemia.And the potential market requirement is enormous for Xuezhikang and another Chinese traditional patent medicine.更多还原